News-Medical.Net on MSN
Researchers identify TRIM13 protein as key driver of immune suppression in sepsis
Dendritic cells (DCs) are increasingly recognized as important contributors to sepsis-associated immune dysfunction. As professional antigen-presenting cells, they bridge innate sensing and durable ...
Mining major Rio Tinto is advancing a research and development project to extract gallium from its alumina refining process in Quebec, supported by funding from the Canadian government. The company ...
Ring Energy, Inc. (NYSE American: REI) ("Ring" or the "Company") today reported operational and financial results for the fourth quarter and full ...
If approved, imlifidase will be the first treatment to address highly sensitized patients awaiting kidney transplantation. LUND, Sweden, ...
Hansa Biopharma AB: PDUFA Action Date for Hansa Biopharma's Imlifidase BLA Set for December 19, 2026
If approved, imlifidase will be the first treatment to address highly sensitized patients awaiting kidney transplantation. LUND, Sweden, March 4, 2026 /PRNewswire/ -- Hansa Biopharma ...
Alzheimer disease (AD) is the most common cause of dementia and one of the leading causes of death in adults age 65 y or ...
Rottenstone Gold Inc. reports update to its previously announced proposed transaction involving certain royalty interests and other related proposed corporate developments . In connection with the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results